Ceft Biopharma

ZEVALIN

Manufacturer:

Ceft Biopharma

Zevalin HCPCS:

A9543

HCPCS Code Descriptor:

Yttrium y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries

Category:

A Code

Zevalin NDCs:

72893-0007-04

Primary Type:

Radiopharmaceutical

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zevalin:

ZEVALIN is a Radiopharmaceutical drug manufactured by Ceft Biopharma and administered via the Intravenous route of administration. The A Code: A9543 is aligned to the drug ZEVALIN.

ACCESS PRICING AND MORE BY REGISTERING

A9543 Added Date:

January 1, 2006

A9543 Effective Date:

January 1, 2006

A9543 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Zevalin billing and coding information.
Our team did not identify a source for Zevalin patient assistance information. Please reach out to our team if you feel that this is a mistake.
ZEVALIN prescribing information can be found at the link below:
Information regarding ZEVALIN’s side effects can be found at MedlinePlus